AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors

Sharon M. Landers¹, Angela D. Bhalla¹, XiaoYan Ma¹, Kristelle Lusby², Davis Ingram³, Ghadah Al Sanna¹⁴, Wei-Lien Wang³, Alexander J. Lazar³, Keila E. Torres¹*

¹Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
²Department of Surgery, Division of Plastic Surgery, Indianapolis University School of Medicine, Indianapolis, IN, USA
³Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
⁴Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston TX, USA

*Corresponding Author: Dr. Keila E. Torres, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Tel: (713) 792-4242; E-mail: ketorres@mdanderson.org

Received: 12 May 2020; Accepted: 04 June 2020; Published: 15 June 2020

Citation: Sharon M. Landers, Angela D. Bhalla, XiaoYan Ma, Kristelle Lusby, Davis Ingram, Ghadah Al Sanna, Wei-Lien Wang, Alexander J. Lazar, Keila E. Torres. AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors. Journal of Cancer Science and Clinical Therapeutics 4 (2020): 189-203.
Supplemental Figure 1: AXL knockdown enhances MPNST sensitivity to MEK1/2 inhibition *in vivo*. AXL knockdown enhances the effects of the MEK inhibitor PD0325901 on the growth of MPNST724-NT xenografts (A) and MPNST724-AXLsh1 xenografts (B). (C) IHC analysis of AXL, pAXL, pMEK1/2, pERK, Ki67, and cleaved caspase 3 (CC3) expression in MPNST724 xenografts treated with vehicle or PD0325901. (D) Quantification of Ki-67 IHC staining.